Pacira Pharma (PCRX) Tops Q1 EPS by 8c; EXPAREL Sales Rose 14%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Mizuho Securities Cuts Price Target on Pacira Pharma (PCRX); Sights Conservatism
May 3, 2016 7:22 AM EDTMizuho Securities maintained a Buy rating on Pacira Pharmaceuticals (NASDAQ: PCRX), and cut the price target to $64.00 (from $79.00), following the company's 1Q earnings report. PCRX reported revenues of $65.5M and an adjusted EPS of $0.14 vs. the consensus estimates of $66.9M and $0.07. There was... More



